| Bioactivity | CDD0102 is a potent M1 Muscarinic receptor agonist. |
| Target | mAChR |
| Invitro | CDD0102 (CDD-0102) is an efficacious muscarinic agonist in cell lines expressing M1 receptors. CDD0102 displays much lower activity at M3 and M5 receptors[1]. |
| In Vivo | After i.p. injections, CDD0102 (CDD-0102) crosses the blood-brain barrier (BBB) in a dose-dependent manner. In toxicological studies, the LD50 of CDD0102 is 190 mg/kg following i.p. injections and greater than 1,000 mg/kg following oral administration. In follow-up studies, after oral administration at a dose of 10 mg/kg, CDD0102 fully reverses memory deficits associated with IgG-192 saporin administration. Again, no side effects are observed at this dose[1]. |
| Name | CDD0102 |
| CAS | 146422-58-4 |
| Formula | C8H12N4O |
| Molar Mass | 180.21 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Messer WS Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):187-93. |